1. Home
  2. ATYR vs NC Comparison

ATYR vs NC Comparison

Compare ATYR & NC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • NC
  • Stock Information
  • Founded
  • ATYR 2005
  • NC 1913
  • Country
  • ATYR United States
  • NC United States
  • Employees
  • ATYR N/A
  • NC N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • NC Coal Mining
  • Sector
  • ATYR Health Care
  • NC Energy
  • Exchange
  • ATYR Nasdaq
  • NC Nasdaq
  • Market Cap
  • ATYR 228.1M
  • NC 232.4M
  • IPO Year
  • ATYR 2015
  • NC N/A
  • Fundamental
  • Price
  • ATYR $3.03
  • NC $32.39
  • Analyst Decision
  • ATYR Strong Buy
  • NC
  • Analyst Count
  • ATYR 4
  • NC 0
  • Target Price
  • ATYR $19.25
  • NC N/A
  • AVG Volume (30 Days)
  • ATYR 927.6K
  • NC 13.5K
  • Earning Date
  • ATYR 11-07-2024
  • NC 10-30-2024
  • Dividend Yield
  • ATYR N/A
  • NC 2.81%
  • EPS Growth
  • ATYR N/A
  • NC N/A
  • EPS
  • ATYR N/A
  • NC N/A
  • Revenue
  • ATYR $235,000.00
  • NC $224,047,000.00
  • Revenue This Year
  • ATYR N/A
  • NC N/A
  • Revenue Next Year
  • ATYR $2,057.69
  • NC N/A
  • P/E Ratio
  • ATYR N/A
  • NC N/A
  • Revenue Growth
  • ATYR N/A
  • NC 1.12
  • 52 Week Low
  • ATYR $1.14
  • NC $25.19
  • 52 Week High
  • ATYR $3.80
  • NC $38.66
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 51.78
  • NC 60.81
  • Support Level
  • ATYR $2.88
  • NC $30.00
  • Resistance Level
  • ATYR $3.80
  • NC $31.24
  • Average True Range (ATR)
  • ATYR 0.24
  • NC 1.11
  • MACD
  • ATYR -0.07
  • NC -0.05
  • Stochastic Oscillator
  • ATYR 22.22
  • NC 56.25

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About NC NACCO Industries Inc.

NACCO Industries Inc is a holding company that operates in the mining and natural resource industries. It has three operating segments that are coal mining, North American mining (NA mining), and minerals management. The majority of its revenue is from the coal mining segment. This segment operates surface coal mines under long-term contracts with power generation companies and an activated carbon producer pursuant to a service-based business model. The NA mining segment provides value-add contract mining and services for producers. Minerals management generates income from royalty-based leases by acquiring and promoting oil, gas, and coal mineral interests. The company is diversifying beyond coal mining due to political and economic pressures associated with carbon emissions.

Share on Social Networks: